Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TB-403 |
Synonyms | |
Therapy Description |
TB-403 (RO5323441) is an antibody directed against Placental Growth Factor (PLGF), which inhibits binding of PLGF to VEGFR1, potentially resulting in decreased tumor growth (PMID: 22333707, PMID: 25665807). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TB-403 | RG7334|RO5323441 | TB-403 (RO5323441) is an antibody directed against Placental Growth Factor (PLGF), which inhibits binding of PLGF to VEGFR1, potentially resulting in decreased tumor growth (PMID: 22333707, PMID: 25665807). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02748135 | Phase Ib/II | TB-403 | A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma | Completed | USA | 0 |